BMS and Otsuka Extend Abilify Partnership
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 4 (Table of Contents)
Published: 7 Apr-2009
DOI: 10.3833/pdr.v2009.i4.1088 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Bristol-Myers Squibb is extending its partnership with Japan’s Otsuka Pharmaceuticals until 2015 on the US sales of their blockbuster psychiatric drug, Abilify® (aripiprazole)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS